» Articles » PMID: 29641463

ITRAQ Quantitative Proteomic Analysis of Vitreous from Patients with Retinal Detachment

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Apr 12
PMID 29641463
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Rhegmatogenous retinal detachment (RRD) is a potentially blinding condition characterized by a physical separation between neurosensory retina and retinal pigment epithelium. Quantitative proteomics can help to understand the changes that occur at the cellular level during RRD, providing additional information about the molecular mechanisms underlying its pathogenesis. In the present study, iTRAQ labeling was combined with two-dimensional LC-ESI-MS/MS to find expression changes in the proteome of vitreous from patients with RRD when compared to control samples. A total of 150 proteins were found differentially expressed in the vitreous of patients with RRD, including 96 overexpressed and 54 underexpressed. Several overexpressed proteins, several such as glycolytic enzymes (fructose-bisphosphate aldolase A, gamma-enolase, and phosphoglycerate kinase 1), glucose transporters (GLUT-1), growth factors (metalloproteinase inhibitor 1), and serine protease inhibitors (plasminogen activator inhibitor 1) are regulated by HIF-1, which suggests that HIF-1 signaling pathway can be triggered in response to RRD. Also, the accumulation of photoreceptor proteins, including phosducin, rhodopsin, and s-arrestin, and vimentin in vitreous may indicate that photoreceptor degeneration occurs in RRD. Also, the accumulation of photoreceptor proteins, including phosducin, rhodopsin, and s-arrestin, and vimentin in vitreous may indicate that photoreceptor degeneration occurs in RRD. Nevertheless, the differentially expressed proteins found in this study suggest that different mechanisms are activated after RRD to promote the survival of retinal cells through complex cellular responses.

Citing Articles

Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy.

Li H, Lyu X, Rong A, Bi Y, Xu W, Cui H Int J Ophthalmol. 2024; 17(10):1816-1827.

PMID: 39430009 PMC: 11422360. DOI: 10.18240/ijo.2024.10.07.


Proteomic Analysis of Aqueous Humor in Central Retinal Artery Occlusion: Unveiling Novel Insights Into Disease Pathophysiology.

Shahror R, Shosha E, Ji M, Morris C, Wild M, Zaman B Transl Vis Sci Technol. 2024; 13(8):30.

PMID: 39163016 PMC: 11343007. DOI: 10.1167/tvst.13.8.30.


A Temporal Association between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 Inhibitor: A Case Report.

Chantarasorn Y, Funilkul K Case Rep Ophthalmol. 2024; 15(1):614-620.

PMID: 39144648 PMC: 11324243. DOI: 10.1159/000540014.


4D label-free proteomic analysis of vitreous from patients with rhegmatogenous retinal detachment.

Huo Q, Zhu M, Yang W, Wang Y, Chen S Int J Ophthalmol. 2023; 16(4):523-531.

PMID: 37077476 PMC: 10089892. DOI: 10.18240/ijo.2023.04.05.


Proteomics profiling of vitreous humor reveals complement and coagulation components, adhesion factors, and neurodegeneration markers as discriminatory biomarkers of vitreoretinal eye diseases.

Santos F, Ciordia S, Mesquita J, Cruz C, Sousa J, Passarinha L Front Immunol. 2023; 14:1107295.

PMID: 36875133 PMC: 9978817. DOI: 10.3389/fimmu.2023.1107295.


References
1.
Nakano K, Chen J, Tarr G, Yoshida T, Flynn J, Bitensky M . Rethinking the role of phosducin: light-regulated binding of phosducin to 14-3-3 in rod inner segments. Proc Natl Acad Sci U S A. 2001; 98(8):4693-8. PMC: 31896. DOI: 10.1073/pnas.071067198. View

2.
Li M, Li H, Jiang P, Liu X, Xu D, Wang F . Investigating the pathological processes of rhegmatogenous retinal detachment and proliferative vitreoretinopathy with metabolomics analysis. Mol Biosyst. 2014; 10(5):1055-62. DOI: 10.1039/c3mb70386j. View

3.
Kim T, Kim S, Kim K, Kang U, Lee C, Park K . Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics. 2007; 7(22):4203-15. DOI: 10.1002/pmic.200700745. View

4.
Im E, Kazlauskas A . The role of cathepsins in ocular physiology and pathology. Exp Eye Res. 2006; 84(3):383-8. DOI: 10.1016/j.exer.2006.05.017. View

5.
Zhou X, Melcher K, Xu H . Structure and activation of rhodopsin. Acta Pharmacol Sin. 2012; 33(3):291-9. PMC: 3677203. DOI: 10.1038/aps.2011.171. View